When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
BMS-777607
LCRF-0004
MET
MST1
Malignant Pleural Mesothelioma
RON
RTK
TAM
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
10
2018
accepted:
31
01
2019
entrez:
14
3
2019
pubmed:
14
3
2019
medline:
14
3
2019
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive inflammatory cancer with a poor survival rate. Treatment options are limited at best and drug resistance is common. Thus, there is an urgent need to identify novel therapeutic targets in this disease in order to improve patient outcomes and survival times. MST1R (RON) is a trans-membrane receptor tyrosine kinase (RTK), which is part of the c-MET proto-oncogene family. The only ligand recognized to bind MST1R (RON) is Macrophage Stimulating 1 (MST1), also known as Macrophage Stimulating Protein (MSP) or Hepatocyte Growth Factor-Like Protein (HGFL). In this study, we demonstrate that the MST1-MST1R (RON) signaling axis is active in MPM. Targeting this pathway with a small molecule inhibitor, LCRF-0004, resulted in decreased proliferation with a concomitant increase in apoptosis. Cell cycle progression was also affected. Recombinant MST1 treatment was unable to overcome the effect of LCRF-0004 in terms of either proliferation or apoptosis. Subsequently, the effect of an additional small molecular inhibitor, BMS-777607 (which targets MST1R (RON), MET, Tyro3, and Axl) also resulted in a decreased proliferative capacity of MPM cells. In a cohort of MPM patient samples, high positivity for total MST1R by IHC was an independent predictor of favorable prognosis. Additionally, elevated expression levels of MST1 also correlated with better survival. This study also determined the efficacy of LCRF-0004 and BMS-777607 in xenograft MPM models. Both LCRF-0004 and BMS-777607 demonstrated significant anti-tumor efficacy
Identifiants
pubmed: 30863365
doi: 10.3389/fendo.2019.00089
pmc: PMC6399142
doi:
Types de publication
Journal Article
Langues
eng
Pagination
89Références
J Clin Invest. 1999 May;103(9):1277-85
pubmed: 10225971
Oncogene. 2000 Jun 22;19(27):3041-9
pubmed: 10871856
Genes Chromosomes Cancer. 2000 Oct;29(2):147-56
pubmed: 10959094
Carcinogenesis. 2003 Aug;24(8):1291-300
pubmed: 12807733
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Br J Ind Med. 1960 Oct;17:260-71
pubmed: 13782506
Exp Cell Res. 2003 Oct 1;289(2):317-25
pubmed: 14499632
Cancer Res. 2004 Aug 1;64(15):5154-61
pubmed: 15289319
Am J Pathol. 2005 Jun;166(6):1827-40
pubmed: 15920167
Cancer Res. 2005 Jul 15;65(14):6105-10
pubmed: 16024611
Lancet. 2005 Jul 30-Aug 5;366(9483):397-408
pubmed: 16054941
Am J Ind Med. 2005 Dec;48(6):419-31
pubmed: 16299703
Mol Cell. 2005 Dec 22;20(6):881-90
pubmed: 16364913
Cancer Res. 2006 Jan 1;66(1):352-61
pubmed: 16397249
Lung Cancer. 2006 Dec;54(3):399-407
pubmed: 17049671
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
J Med Chem. 2009 Mar 12;52(5):1251-4
pubmed: 19260711
Carcinogenesis. 2009 Jul;30(7):1097-105
pubmed: 19380521
Eur J Cardiothorac Surg. 2010 Mar;37(3):566-72
pubmed: 19781955
Bioorg Med Chem Lett. 2010 May 1;20(9):2745-9
pubmed: 20363625
Br J Cancer. 2010 Jul 27;103(3):430-6
pubmed: 20628377
Oncogene. 2011 Apr 7;30(14):1643-52
pubmed: 21132014
Oncol Res. 2010;19(1):13-22
pubmed: 21141737
Cancer Res. 2011 Mar 1;71(5):1945-55
pubmed: 21212418
Pathology. 2011 Feb;43(2):128-32
pubmed: 21233673
Environ Health Perspect. 2011 Apr;119(4):514-8
pubmed: 21463977
Cancer Biol Ther. 2011 Jul 1;12(1):9-46
pubmed: 21543897
Carcinogenesis. 2011 Aug;32(8):1151-6
pubmed: 21565828
Pathol Res Pract. 2011 Aug 15;207(8):463-7
pubmed: 21723047
Mol Cancer. 2011 Jul 12;10:82
pubmed: 21749705
J Thorac Oncol. 2011 May;6(5):864-74
pubmed: 21774103
EMBO Mol Med. 2011 Nov;3(11):623-36
pubmed: 21953712
Genes Cancer. 2011 Jul;2(7):753-62
pubmed: 22207901
J Thorac Oncol. 2012 Mar;7(3):599-606
pubmed: 22246193
Clin Exp Metastasis. 2012 Mar;29(3):253-61
pubmed: 22286523
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Rev Cancer. 2012 May 24;12(6):387-400
pubmed: 22622641
Invest New Drugs. 2013 Aug;31(4):833-44
pubmed: 23275061
Br J Cancer. 2013 Feb 19;108(3):621-8
pubmed: 23361052
Nat Rev Cancer. 2013 Jul;13(7):466-81
pubmed: 23792360
PLoS One. 2013 Jul 29;8(7):e69992
pubmed: 23922886
Sci Rep. 2013;3:2560
pubmed: 23994953
Oncogenesis. 2013 Oct 07;2:e76
pubmed: 24100611
Cold Spring Harb Perspect Biol. 2013 Nov 01;5(11):a009076
pubmed: 24186067
Cancer Res. 2014 Feb 1;74(3):884-95
pubmed: 24305878
Cell Rep. 2014 Jan 16;6(1):141-54
pubmed: 24388747
Int J Cancer. 2014 Aug 15;135(4):1002-6
pubmed: 24458568
Cell Death Dis. 2014 Apr 10;5:e1167
pubmed: 24722292
Br J Cancer. 2014 May 13;110(10):2479-88
pubmed: 24762959
Clin Cancer Res. 2014 Aug 1;20(15):4059-4074
pubmed: 24919575
Expert Opin Investig Drugs. 2015 Jan;24(1):95-110
pubmed: 25315907
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18661-6
pubmed: 25512530
BMC Cancer. 2014 Dec 17;14:970
pubmed: 25518851
EMBO Rep. 2015 Mar;16(3):280-96
pubmed: 25680965
Oncotarget. 2015 Feb 28;6(6):3507-18
pubmed: 25784650
Bioorg Med Chem Lett. 2015 Jun 15;25(12):2527-31
pubmed: 25953155
Bioorg Med Chem Lett. 2015 Sep 1;25(17):3706-10
pubmed: 26112445
Ann Oncol. 2015 Sep;26 Suppl 5:v31-9
pubmed: 26223247
Bioorg Med Chem Lett. 2015 Sep 15;25(18):3810-5
pubmed: 26243370
Oncotarget. 2016 Mar 1;7(9):9876-89
pubmed: 26848524
Mol Cell Proteomics. 2017 May;16(5):891-910
pubmed: 28331001
Mol Cancer. 2018 Feb 19;17(1):45
pubmed: 29455668
Int J Mol Sci. 2018 Nov 12;19(11):null
pubmed: 30424481
Lancet. 1995 Mar 4;345(8949):535-9
pubmed: 7776771
EMBO J. 1994 Aug 1;13(15):3524-32
pubmed: 8062829
Oncogene. 1995 Dec 21;11(12):2627-37
pubmed: 8545120